Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Research & Development (2021 - 2025)

Verrica Pharmaceuticals has reported Research & Development over the past 5 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Research & Development at $2.5 million for Q4 2025, up 115.75% from a year ago — trailing twelve months through Dec 2025 was $8.9 million (down 25.21% YoY), and the annual figure for FY2025 was $8.9 million, down 25.21%.
  • Research & Development for Q4 2025 was $2.5 million at Verrica Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Over the last five years, Research & Development for VRCA hit a ceiling of $6.5 million in Q3 2023 and a floor of -$10.3 million in Q4 2021.
  • Median Research & Development over the past 5 years was $2.9 million (2022), compared with a mean of $2.8 million.
  • Biggest five-year swings in Research & Development: surged 134.17% in 2023 and later tumbled 78.05% in 2024.
  • Verrica Pharmaceuticals' Research & Development stood at -$10.3 million in 2021, then surged by 129.48% to $3.0 million in 2022, then skyrocketed by 75.69% to $5.3 million in 2023, then tumbled by 78.05% to $1.2 million in 2024, then skyrocketed by 115.75% to $2.5 million in 2025.
  • The last three reported values for Research & Development were $2.5 million (Q4 2025), $2.2 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.